CN115151249A - 一种含脱辅基水母蛋白和姜黄素的组合物和方法 - Google Patents
一种含脱辅基水母蛋白和姜黄素的组合物和方法 Download PDFInfo
- Publication number
- CN115151249A CN115151249A CN202180016394.8A CN202180016394A CN115151249A CN 115151249 A CN115151249 A CN 115151249A CN 202180016394 A CN202180016394 A CN 202180016394A CN 115151249 A CN115151249 A CN 115151249A
- Authority
- CN
- China
- Prior art keywords
- composition
- subject
- administered
- symptom
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 76
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 40
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 239000004148 curcumin Substances 0.000 title claims abstract description 37
- 229940109262 curcumin Drugs 0.000 title claims abstract description 37
- 108010041089 apoaequorin Proteins 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 30
- 208000024891 symptom Diseases 0.000 claims abstract description 20
- 208000002193 Pain Diseases 0.000 claims abstract description 16
- 230000036651 mood Effects 0.000 claims abstract description 13
- 230000007958 sleep Effects 0.000 claims abstract description 13
- 230000003920 cognitive function Effects 0.000 claims abstract description 10
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 9
- 230000036506 anxiety Effects 0.000 claims abstract description 9
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 8
- 235000016709 nutrition Nutrition 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000003340 mental effect Effects 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 230000000091 immunopotentiator Effects 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 230000018678 bone mineralization Effects 0.000 claims description 3
- 230000030833 cell death Effects 0.000 claims description 3
- 230000032823 cell division Effects 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000004118 muscle contraction Effects 0.000 claims description 3
- 230000008587 neuronal excitability Effects 0.000 claims description 3
- 230000035699 permeability Effects 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 108010000239 Aequorin Proteins 0.000 description 12
- 230000006872 improvement Effects 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000003765 sweetening agent Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 244000163122 Curcuma domestica Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000003373 curcuma longa Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 241000242583 Scyphozoa Species 0.000 description 4
- 241000234314 Zingiber Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- -1 bile acid salts Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241001061264 Astragalus Species 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 244000133098 Echinacea angustifolia Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000006533 astragalus Nutrition 0.000 description 3
- 229940093797 bioflavonoids Drugs 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000003931 cognitive performance Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000014134 echinacea Nutrition 0.000 description 3
- 235000008384 feverfew Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 210000004233 talus Anatomy 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 2
- 241000242764 Aequorea victoria Species 0.000 description 2
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 2
- 235000010081 allicin Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 2
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- CJIIERPDFZUYPI-UHFFFAOYSA-N oxidized Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(=O)NC1=NC=C(C=2C=CC(O)=CC=2)N=C1CC1=CC=CC=C1 CJIIERPDFZUYPI-UHFFFAOYSA-N 0.000 description 2
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001062872 Cleyera japonica Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001367069 Hemiargus ceraunus Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 108010010165 curculin Proteins 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000014569 mints Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- XMGMFRIEKMMMSU-UHFFFAOYSA-N phenylmethylbenzene Chemical group C=1C=CC=CC=1[C]C1=CC=CC=C1 XMGMFRIEKMMMSU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 230000002455 vasospastic effect Effects 0.000 description 1
- 208000027491 vestibular disease Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Abstract
本发明提供了包含脱辅基水母蛋白和姜黄素的组合物及其用于治疗症状和病症,例如精神障碍、焦虑、认知功能、睡眠质量、精力质量、情绪质量、记忆质量或疼痛的方法。
Description
相关申请的交叉引用
本国际申请要求2020年2月24日提交的第62/980,785美国临时申请的优先权,通过引用纳入本文。
关于联邦资助研究或开发的声明
不适用。
发明领域
本发明总体上涉及可用于维持人类健康的组合物。具体地,本发明涉及含脱辅基水母蛋白(apoaequorin)和姜黄素的营养组合物。
发明内容
本发明在改善和/或维持人类健康方面提供了优于现有组合物和方法的各种优点。这种组合物包括与可接受的载体组合的脱辅基水母蛋白和姜黄素制剂,以便通过多种途径施用于对象。
因此,本发明涉及包含有效量的脱辅基水母蛋白和姜黄素与可接受的载体组合的组合物。在一些实施方式中,本发明涉及包含有效量的脱辅基水母蛋白和姜黄素与可接受的载体组合的营养组合物。在一些实施方式中,除了脱辅基水母蛋白和姜黄素外,营养组合物还包括至少一种被认为提供营养益处的其他组分,例如免疫增强剂、抗炎剂、抗氧化剂、抗病毒剂或其混合物。在某些实施方式中,脱辅基水母蛋白和姜黄素组合物以选自片剂、胶囊剂、溶液剂、混悬剂、糖浆、饮料或口服或眼用制剂的单位剂型提供。
在另一方面,本发明涉及治疗与钙失衡相关的症状或病症的方法,所述方法包括向需要这种治疗的对象施用有效量的脱辅基水母蛋白和姜黄素。
根据本发明的方法可用于治疗与人类健康相关的多种症状或病症,包括但不限于精神障碍、焦虑、认知功能、睡眠质量、精力质量、情绪质量、疼痛、记忆质量。在一些实施方式中,病症的症状在生理上与神经元兴奋性、肌肉收缩、膜通透性、细胞分裂、激素分泌、骨矿化或缺血后的细胞死亡有关。在这样的方法中,脱辅基水母蛋白和姜黄素优选以营养组合物的形式施用于对象。
在又一个实施方式中,本发明包括脱辅基水母蛋白和姜黄素在制备用于治疗与施用该营养组合物的对象的人类健康相关的症状或病症的营养组合物中的用途。由此类组合物治疗的示例性症状或病症包括与精神障碍、焦虑、认知功能、睡眠、精力、情绪、疼痛或记忆相关的那些。
因此,本发明还涉及脱辅基水母蛋白和姜黄素用于治疗对象的上述症状或病症,包括与例如对象的精神障碍、焦虑、认知功能、睡眠、精力、情绪、疼痛、或记忆相关的症状或病症。
本发明提供了优于现有组合物和方法的各种优点,因为它提供了对象精神和身体健康的总体改善。
在阅读以下说明书和权利要求之后,本发明的其他目的、特征和优点将显而易见。
附图简要说明
图1提供了显示以下区域的相对于分数基线的百分比变化vs.天数(0-90)的图表:睡眠的整体质量、精力、情绪、疼痛和总体健康状况。
图2示出显示56名参与者每天服用脱辅基水母蛋白(10mg)的数据图表。参与者的评估时间为8天到30天。记忆力研究显示30天后记忆力有统计学意义的改善(hp<.05)。57%的参与者在总体记忆方面有所改善,51%在保留信息方面有所改善,84%在记住行车路线方面有所改善,66%在单词回忆方面有所改善。N=56;66%女性,34%男性,平均年龄=56岁;范围20-78岁。
图3提供显示标准化认知功能问卷中相对于分数基线的百分比变化vs.天数(0-90天)的图表。
具体实施方式
概述
在描述本发明的材料和方法之前,应理解的是,本发明不限于所描述的具体方法和材料,因为这些可以变化。还应理解,本文所用术语的目的仅是描述具体实施方式,不应用来限制本发明的范围,本发明的范围仅受所附权利要求书的限制。
必须注意到,本文和所附权利要求书所用的单数形式“一个”、“一种”和“所述”包括复数含义,除非上下文另有明确说明。同样,术语“一个”(或“一种”)、“一个或多个”和“至少一个”在本文中可互换使用。还应当注意,术语“包括”、“包含”、和“具有”可以互换使用。
除非另外定义,否则,本文中所使用的所有技术和科学术语都具有本发明所属领域普通技术人员通常所理解的同样含义。虽然可采用与本文所述类似或等同的任何方法和材料实施或测试本发明,但在此描述的是优选的方法和材料。本文特别提及的所有出版物和专利均通过引用并入本文,目的包括描述和公开可能与本发明结合使用的出版物中报告的化学品、仪器、统计分析和方法。本说明书引用的所有参考文献都应看作对本领域技术水平的指示。本文中所有内容均不应解释为承认本发明不是先于这些公开内容的在先发明。
本发明的内容
水母蛋白是一种最初从发光水母和其他海洋生物中分离出来的光感蛋白。水母蛋白复合物包含分子量为22,285道尔顿的脱辅基水母蛋白、分子氧和发光体腔肠素。当三个Ca2+离子与该复合物结合时,腔肠素被氧化成腔肠酰胺,同时释放出二氧化碳和蓝光。水母蛋白不由细胞输出或分泌,也不会被分隔或隔离在细胞内。因此,水母蛋白测量已被用于检测在较长时间内发生的Ca2+变化。在几个实验系统中,水母蛋白的发光在细胞加载后数小时到数天都可以检测到。还已知水母蛋白也不会破坏细胞功能或胚胎发育。
由于其依赖于Calf-的发光,水母蛋白复合物已被广泛用作细胞内Ca2+指示剂。发光水母(Aequorea victoria)水母蛋白已专门用于:(1)分析单个肾上腺嗜铬细胞对烟碱型胆碱能激动剂的分泌反应;(2)阐明Ca2+释放在心肌损伤中的作用;(3)证明受精过程中Ca2+的大量释放;(4)研究发育中的鸡成肌细胞中肌浆网Ca2+泵表达的调控;(5)校准微量移液器,其进样量低至3皮升。
脱辅基水母蛋白的分子量约为22kDa。脱辅基水母蛋白可用于通过还原脱辅基水母蛋白中的二硫键来再生水母蛋白。负载钙的脱辅基水母蛋白保留了与含有结合底物的未反应光感蛋白相同的紧凑结构和整体折叠样式。
从发光水母(Aequorea victoria)中常规纯化水母蛋白需要费力的提取工序,有时会产生基本上异质的制剂或对研究中的生物体有毒的制剂。两吨水母通常会产生大约125mg的纯化光感蛋白。相反,重组水母蛋白优选通过从转基因大肠杆菌(Eseherichiacoli)中纯化脱辅基水母蛋白,然后在体外用纯腔肠素重构水母蛋白复合物来生产。可用于本发明的脱辅基水母蛋白已在文献中描述并且可通过本领域技术人员已知的纯化方案和/或合成商业获得,如S.Inouye,S.Zenno,Y.Sakaki,和F.Tsuji.,“脱辅基水母蛋白的高水平表达和纯化(High level expression and purification of apoaequorin)”。(1991)蛋白质表达和纯化2,122-126。
本发明涉及向对象施用含有脱辅基水母蛋白和姜黄素的组合物以纠正或维持该对象的钙平衡,从而改善但不限于精神障碍、焦虑、认知功能、睡眠质量、精力质量、情绪质量、疼痛、记忆质量。姜黄素(双阿魏酰甲烷;1,7-双[4-羟基-3-甲氧基苯基]-1,6-庚二烯-3,5-二酮)是一种脂溶性分子和疏水性多酚衍生物。姜黄素的已知标识符是CAS编号:458-37-7。其化学式为C21H20O6,摩尔质量为368.39g·mol-1,熔点为183℃(361°F;456K)。
姜黄素及其单甲氧基和二甲氧基衍生物(称为类姜黄素、双去甲氧基姜黄素、去甲氧基姜黄素和四氢姜黄素)是提取过程得到的姜黄素制剂的主要成分。市售姜黄素有时可以包含大约77%双阿魏酰甲烷、17%去甲氧基姜黄素和6%双去甲氧基姜黄素。姜黄素是用溶剂从姜黄(黄姜)植物的干燥和磨碎的根茎中提取而获得的。姜黄历来在印度阿育吠陀医学中用于治疗多种疾病,但直到20世纪,科学研究才确定姜黄素是其大部分生物活性的原因。
姜黄素已成为众多临床前和临床研究的主题,因此其抗炎和抗氧化能力已得到充分证明:它具有调节细胞氧化平衡的能力,以不同方式参与多种机制;特别是,它抑制一系列具有强烈炎症活性的因子(COX1和2、TNF、脂氧合酶和干扰素-γ)。最后,其作为抗肿瘤药的功效已在体外得到证实(Bengmark S.,JPEN,2006,30(1):45-51)。
姜黄素(及其衍生物,例如用作前药的酯类)可以原样获得(通常与以较小比例存在的其他类姜黄素相关,例如姜黄素复合物),或作为生物姜黄素(BCM-)与增加其生物利用度的油和聚合物相关(US20070148263),或与胡椒碱组合配制(Shobha等,Planta Med,1998,64:353-56),或作为微乳剂或纳米乳剂/纳米分散剂获得,其使用卵磷脂和/或脂肪酸和/或甘油三酯以及任选的表面活性剂,例如吐温80,以稳定分子并使其更具生物利用度。
还应当理解,二芳基类庚酮(diarylheptanoid)被认为是类姜黄素(例如姜黄素)所属的一类化合物。其他类似的二芳基类庚酮,例如可以从生姜中获得的那些,可能具有与类姜黄素(例如姜黄素)相似的特性。应理解虽然本文详细描述了类姜黄素(例如姜黄素),但应理解其他二芳基类庚酮可具有相似或相同的生物学特性和效果,并且其可包括在如本文所述的此类组合物中并且可用于本文所述的治疗方法中。
此外,人们越来越关注研发可用于提高老年人和年轻人,在日常工作中需要特别高的记忆力和注意力的个人,包括学生、建筑工人、司机、飞行员、医生、销售人员、行政人员、家庭主妇、“高绩效专业人士”和承受精神或日常压力的人,以及容易出现精神不稳定和剧烈情绪波动的人的注意力、学习能力、记忆力和警觉性的治疗化合物。一种能够提供平衡精神状态的治疗产品将有助于大部分生活在高压力、高绩效生活的人的生活更有成效。
因此,在一些实施方式中,本发明的方法包括将脱辅基水母蛋白和姜黄素作为活性成分给药以改善注意力持续时间。在其他实施方式中,本发明提供的方法包括将含有脱辅基水母蛋白和姜黄素的组合物与一种或多种具有已知治疗或营养价值的其他药剂组合给药。脱辅基水母蛋白和姜黄素的特别优选的应用是用于治疗与注意力持续时间相关的一种或多种症状和病症。
如本文所用,术语“警觉”、“持续注意力”和“注意力持续时间”是指个体在一段时间内关注刺激或事物的能力。换言之,在一段时间内保持专注和警觉的能力。
如本文所用,术语“治疗”包括预防性治疗以及疾病缓解治疗。如本文所用,术语“减少”、“减轻”、“压制”和“抑制”具有通常理解的减少或降低的含义。如本文所用,术语“进展”意指范围或严重性增加、进展、增长或变得更糟。如本文所用,术语“复发”是指疾病缓解后复发。
如本文所用,术语“给药”是指使患者、组织、器官或细胞与脱辅基水母蛋白和姜黄素接触。如本文所用,给药可以在体外,即在试管中,或在体内,即在活生物体例如人的细胞或组织中完成。在优选的实施方式中,本发明包括将可用于本发明的制剂或组合物向患者或对象给药。“患者”或“对象”,在本文中等同使用,是指哺乳动物,优选人,其:(1)患有钙失衡相关疾病,可通过给予脱辅基水母蛋白和姜黄素来治愈或治疗;或(2)易患钙失衡相关疾病,可通过给予脱辅基水母蛋白和姜黄素来预防。
如本文所用,术语“有效量”和“治疗有效量”是指足以产生所需的治疗反应而没有过度不良副作用例如毒性、刺激或过敏反应的活性剂的量。显然,具体的“有效量”将视各种因素而不同,例如进行治疗的特定病症、患者的身体状况、进行治疗动物的类型、治疗的持续时间、并行治疗(如果有)的性质和所用具体制剂以及化合物或其衍生物的结构。在这种情况下,如果某个量会导致以下一项或多项,该量将被视为治疗有效:与未给予该组合的对象相比,对象的精神障碍、焦虑、认知功能、睡眠质量、精力质量、情绪质量、疼痛、记忆质量的预防、逆转、稳定或改善。在一些实施方式中,病症的症状在生理上与神经元兴奋性、肌肉收缩、膜通透性、细胞分裂、激素分泌、骨矿化或缺血后的细胞死亡有关。最优有效量可以由本领域普通技术人员通过常规实验容易地确定。
在对象口服给药的某些优选组合物中,将脱辅基水母蛋白以约10mg/剂至80mg/剂、优选20mg/剂至70mg/剂、更优选30mg/剂至60mg/剂的剂量配制成制剂。另一方面,姜黄素以约80mg/剂至1200mg/剂的剂量配制成制剂,对象的优选剂量为约600mg/剂至800mg/剂。
可以将常规赋形剂例如稀释剂、配体、缓冲剂、甜味剂、调味剂、着色剂、增溶剂、崩解剂、润湿剂和其他常用赋形剂添加到制剂中。合适的调味剂包括天然香料、人造香料和薄荷,例如椒样薄荷、薄荷醇、人造香草、肉桂、各种水果香料,可单独和混合等使用。调味剂的使用量通常变化,取决于单个调味剂,例如,可以在最终组合物重量的约0.5至约3重量%的范围内变化。
在使用甜味剂的情况下,本发明可包括本领域熟知的那些甜味剂,包括天然和人造甜味剂。因此,可以从以下非限制性列表中选择额外的甜味剂:糖,例如蔗糖、葡萄糖(玉米糖浆)、转化糖、果糖及其混合物;糖精及其各种盐类,如钠盐或钙盐;环己基氨基磺酸及其钠盐等各种盐类;二肽甜味剂,如阿斯巴甜;二氢查耳酮;甘草甜素;甜叶菊(Steviarebaudiana)(甜菊糖苷);以及糖醇,例如山梨糖醇、山梨糖醇糖浆、甘露糖醇、木糖醇等。还考虑作为附加甜味剂的是美国专利No.Re 26,959中描述的不可发酵糖替代物(氢化淀粉水解物)。还考虑的是德国专利第2,001,017.7号中描述的合成甜味剂3,6-二氢-6-甲基-1-1-2,3-噁噻嗪-4-酮-2,2-二氧化物,特别是其钾盐(安赛蜜-K)、钠盐和钙盐。通常,甜味剂的用量会根据甜味剂的类型和最终产品的所需口味而变化。例如,天然甜味剂的用量可高达约5重量%,而人造甜味剂的用量可高达约1重量%。
可用于本发明的着色剂包括颜料,例如二氧化钛,其掺入量可高达约1重量%,优选高达约0.6重量%。此外,着色剂可包括其他适用于食品、药物和化妆品应用的染料,称为F.D.&C.染料等。上述使用中可接受的材料优选是水溶性的。说明性实例包括靛蓝染料,称为F.D.&C.蓝2号,它是5,5'-靛蓝二磺酸的二钠盐。类似地,被称为F.D.&C绿1号的染料包含三苯甲烷染料,是4-[4-N-乙基-对-磺基苄基氨基)二苯基亚甲基][1-(N-乙基-N-对-锍苄基)-2,5-环己二烯亚胺]的单钠盐。所有F.D.&C.和D.&C.染料及其相应的化学结构的详述可以在柯克奥斯默化工技术百科全书(Kirk-Othmer Encyclopedia of ChemicalTechnology),第5卷,第857-884页中找到,该文本相应地通过引用纳入本文。
本发明的组合物还可以包括液体或冻干的或以其他方式干燥的制剂,并包括各种缓冲液内容物(例如Tris-HCl、乙酸盐、磷酸盐)、pH和离子强度的稀释剂、添加剂如白蛋白或明胶以防止表面吸收、洗涤剂(例如Tween 20、Tween 80、Pluronic F68、胆汁酸盐)、增溶剂(例如甘油、聚亚乙基甘油(polyethylene glycerol))、抗氧化剂(例如抗坏血酸、焦亚硫酸钠)、防腐剂(例如硫柳汞、苯甲醇、对羟基苯甲酸酯)、填充物质或张度调节剂(例如乳糖、甘露醇)、聚合物(例如聚乙二醇)与蛋白质的共价连接、与金属离子的络合,或将材料掺入或掺至聚合物(例如聚乳酸、聚乙醇酸或水凝胶)的颗粒制剂中,或掺至脂质体、微乳液、胶束、层状或多层囊泡、红细胞血影或原生质球。此类组合物将影响物理状态、溶解度、稳定性、体内释放速率和体内清除速率。控释或缓释组合物包括在亲脂贮库(例如脂肪酸、蜡、油)中的制剂。
本领域容易理解包含活性成分的组合物的制备。活性治疗成分通常与赋形剂混合,赋形剂是药学上可接受的并与该活性成分相容。合适的赋形剂包括,例如,水,盐水,右旋糖,甘油,乙醇等及其任意组合。此外,该组合物可含有少量辅助物质,例如湿润剂或乳化剂、pH缓冲剂,其增强或保持活性成分的有效性。
可以将活性成分配制成中和的药学上可接受的盐形式的组合物。药学上可接受的盐包括酸加成盐,其由无机酸例如盐酸或磷酸,或有机酸诸如乙酸、酒石酸、扁桃酸等形成。由游离羧基基团形成的盐还可以衍生自无机碱,例如,钠、钾、铵、钙或铁氢氧化物,和有机碱诸如异丙胺、三甲胺、2-乙氨基乙醇、组氨酸、普鲁卡因等。
活性成分的盐优选为药学上可接受的盐。然而,其他盐也可用于制备根据本发明的组合物或其药学上可接受的盐。合适的药学上可接受的盐包括酸加成盐,其可以例如通过将活性成分的溶液与药学上可接受的酸例如盐酸、硫酸、甲磺酸、富马酸、马来酸、琥珀酸、乙酸、苯甲酸、草酸、柠檬酸、酒石酸、碳酸或磷酸的溶液混合而形成。
此外,出于本说明书的目的,“补充剂”是指提供医疗健康益处(包括预防和/或治疗疾病)的食品或食品的一部分。根据本发明的补充剂组合物可以仅包含脱辅基水母蛋白和姜黄素作为活性成分,或者,可以进一步包括与膳食补充剂混合,所述膳食补充剂包括维生素、辅酶、矿物质、草本植物、氨基酸等,通过增加该物质的总摄入量补充饮食。
因此,本发明提供了向患者提供健康益处的方法,包括向对象给予包含脱辅基水母蛋白和姜黄素的补充剂组合物的步骤。此类组合物通常包括“可接受的载体”,如本文所指,其是适用于口服递送的任何载体,包括上述适用于口服途径的药学上可接受的载体。因此,本发明提供了一种用于将药物口服递送给患者的更有利的机制。
在某些实施方式中,根据本发明的组合物包含膳食补充剂,其基于功能进行定义,包括免疫增强剂、抗炎剂、抗氧化剂、抗病毒剂或它们的混合物。
免疫增强剂和/或抗病毒剂可用于加速伤口愈合和改善免疫功能;它们包括松果菊属的提取物或紫锥菊(Echinacea)属的草本植物、接骨木(Sambuca)属的草本植物提取物和白毛茛提取物。黄芪属草本植物也是有效的免疫增强剂,无论是其天然形式还是加工形式。黄芪刺激骨髓和淋巴组织活性免疫细胞中干细胞的发育。锌及其生物活性盐,如葡萄糖酸锌和醋酸锌,在治疗普通感冒时也可作为免疫增强剂。
抗氧化剂包括天然的含硫氨基酸大蒜素,可增加血液中抗氧化酶的水平。含有大蒜素的草本植物或草本植物提取物,如大蒜,也是有效的抗氧化剂。儿茶素和含有儿茶素的草本植物如绿茶的提取物也是有效的抗氧化剂。黄芪属的提取物也显示出抗氧化活性。生物类黄酮,例如槲皮素、橙皮苷、芦丁及其混合物,也可有效作为抗氧化剂。生物类黄酮的主要有益作用可以是保护维生素C在体内免受氧化。这使得更多的维生素C或抗坏血酸可供身体使用。
生物类黄酮如槲皮素也是有效的抗炎剂,并且可以原样用于本发明的组合物中。抗炎草本补充剂和源自植物或草本植物的抗炎化合物也可用作本发明组合物中的抗炎剂。这些包括菠萝蛋白酶(一种在菠萝中发现的蛋白水解酶);茶和荨麻提取物;姜黄,姜黄提取物,或姜黄素(一种从姜黄中分离出来的黄色色素)。
可用于本发明的另一种补充剂是生姜,其衍生自生姜(Zingiber)属的草本植物。由于姜酚和相关的化合物姜烯酚等化合物,已发现其具有强心活性,并在治疗头晕和前庭疾病方面提供益处。生姜在治疗恶心和其他胃病方面也很有效。
有助于重建软组织结构,特别是重建软骨的补充剂可用于治疗关节炎和其他关节疾病疼痛的组合物中。氨基葡糖、硫酸氨基葡糖、软骨素可以来源于多种来源,例如麋鹿鹿茸。还已知海洋脂质复合物、欧米茄3脂肪酸复合物和鱼油可用于治疗与关节炎相关的疼痛。
可用于治疗偏头痛的补充剂包括小白菊(feverfew)和银杏叶(Gingko biloba)。小白菊中的主要活性成分是倍半萜内酯小白菊内酯,它抑制前列腺素的分泌,而前列腺素又通过血管中的血管痉挛活动引起疼痛。小白菊还具有抗炎特性。鱼油由于其血小板稳定和抗血管痉挛作用,也可用于治疗偏头痛。草本植物银杏还通过稳定动脉和改善血液循环来帮助治疗偏头痛。
尽管以上列出的一些补充剂已经描述了其药理作用,但本发明中也可以使用其他添加剂,并且它们的作用在科学文献中有充分的记载。
在考虑以下非限制性实施例的基础上,能够更完整地理解本发明。
实施例
实施例1:在九十(90)天的时间给予脱辅基水母蛋白可提高测试对象的生活质量。
目前的分析是一项开放标签研究,在90天内对32名患者进行了分析,显示睡眠的整体质量、精力、情绪、疼痛和总体健康有所提高。效能的变化是通过一系列标准化问题测验来衡量的。其包括对定性认知测试、睡眠指数、头痛指数和生活质量问卷的评估。研究表明效能有所提高。没有参与者因不良事件而终止研究。
图1所示的结果显示了上述区域的分数相对于基线的百分比变化;已经排除了另一个图表的记忆分数。此处的分析显示在图表上标记为1、2、3、4和5vs.天数(第0天到第90天)。图表显示睡眠的整体质量、精力、情绪、疼痛和总体健康有所提高。基线是研究前阶段已知的。
实施例2:在三十(30)天的时间给予脱辅基水母蛋白可提高测试对象的生活质量。
本研究是一项为期30天对56名参与者的开放标签研究。效能变化是通过记忆筛选工具测量的。如图2所示,该研究早在8天时就显示出记忆力的改善,但在第30天有统计学意义的较大改善。没有参与者因不良事件而终止研究。
实施例3:在九十(90)天的时间给予脱辅基水母蛋白可提高测试对象的认知。
针对32名患者的开放标签研究,目前的分析显示认知能力有所提高。效能的变化是通过一系列标准化认知成套测验来衡量的。该研究表明,早在8天后认知能力就会有所改善,但在第30天以及60-90天时有统计学意义的较大改善。没有参与者因不良事件而终止研究。图3中显示的结果表明,认知能力得分相对于基线的百分比显著增加。注意:超过51%的参与者的认知能力提高。
应理解,本文所述的实施例和实施方式仅用于说明目的,本领域技术人员应了解据此作出的各种修饰或改变,且它们包括在本申请的主旨和权益以及所附权利要求书的范围内。本文引用的所有发表物、专利和专利申请通过引用全文纳入本文以用于所有目的。
本领域的技术人员通过考虑说明书和实施本文所述的发明,将会明显看出本发明的其他实施方式和应用。基于任何原因在本文中引用的所有参考文献,包括所有的杂志文献和美国/外国专利和专利申请,都通过引用具体并全文纳入本文。应理解本发明并不限于本文说明和描述的具体试剂、制剂、反应条件等,但还包括在以下权利要求范围内的其修饰形式。
Claims (20)
1.一种用于改善人类健康的组合物,包含:(a)有效量的脱辅基水母蛋白;(b)有效量的姜黄素;(c)可接受的载体。
2.如权利要求1所述的组合物,其特征在于,所述组合物还包含免疫增强剂、抗炎剂、抗氧化剂、抗病毒剂或其混合物。
3.如权利要求1或2所述的组合物,其特征在于,所述组合物是选自片剂、胶囊剂、溶液剂、混悬剂、糖浆、饮料或口服或眼用制剂的单位剂型。
4.如权利要求1-3中任一项所述的组合物,其特征在于,所述组合物是营养组合物形式。
5.一种用于改善人类健康的方法,包括向需要这种治疗的对象给予权利要求1-4中任一项所述的组合物。
6.如权利要求5所述的方法,其特征在于,所述症状或病症与睡眠相关,并且将权利要求1-3中任一项所述的组合物给予所述对象以改善所述对象的睡眠质量。
7.如权利要求5所述的方法,其特征在于,所述症状或病症与精力相关,并且将权利要求1-4中任一项所述的组合物给予所述对象以改善所述对象的精力质量。
8.如权利要求5所述的方法,其特征在于,所述症状或病症与情绪相关,并且将权利要求1-4中任一项所述的组合物给予所述对象以改善所述对象的情绪质量。
9.如权利要求5所述的方法,其特征在于,所述症状或病症与疼痛相关,并且将权利要求1-4中任一项所述的组合物给予所述对象以减轻所述对象的疼痛。
10.如权利要求5所述的方法,其特征在于,所述症状或病症与记忆相关,并且将权利要求1-4中任一项所述的组合物给予所述对象以改善所述对象的记忆质量。
11.如权利要求5所述的方法,其特征在于,所述症状或病症与精神相关,并且将权利要求1-4中任一项所述的组合物给予所述对象以改善所述对象的精神障碍。
12.如权利要求5所述的方法,其特征在于,所述症状或病症与精神相关,并且将权利要求1-4中任一项所述的组合物给予所述对象以改善所述对象的焦虑。
13.如权利要求5所述的方法,其特征在于,所述症状或病症与精神相关,并且将权利要求1-4中任一项所述的组合物给予所述对象以改善所述对象的认知功能。
14.如权利要求5所述的方法,其特征在于,所述症状或病症与神经元兴奋性、肌肉收缩、膜通透性、细胞分裂、激素分泌、骨矿化或缺血后的细胞死亡有关。
15.如权利要求5-14中任一项所述的方法,其特征在于,所述组合物以营养组合物形式给予所述对象。
16.如权利要求5-14中任一项所述的方法,其特征在于,所述组合物被口服给予所述对象。
17.如权利要求1-4中任一项所述的组合物在制备用于治疗改善给予所述营养组合物的对象的人类健康的营养组合物中的用途。
18.如权利要求1-4中任一项所述的组合物在制备用于改善给予所述营养组合物的对象的精神障碍、焦虑、认知功能、睡眠、精力、情绪、疼痛或记忆的营养组合物中的用途。
19.用于改善对象健康的组合物。
20.用于治疗与对象的精神障碍、焦虑、认知功能、睡眠、精力、情绪、疼痛或记忆相关的症状或病症的组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062980785P | 2020-02-24 | 2020-02-24 | |
US62/980,785 | 2020-02-24 | ||
PCT/US2021/019231 WO2021173550A1 (en) | 2020-02-24 | 2021-02-23 | Apoaequorin and curcumin containing compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115151249A true CN115151249A (zh) | 2022-10-04 |
Family
ID=74875355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180016394.8A Pending CN115151249A (zh) | 2020-02-24 | 2021-02-23 | 一种含脱辅基水母蛋白和姜黄素的组合物和方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230078821A1 (zh) |
EP (1) | EP4110312A1 (zh) |
JP (1) | JP2023515129A (zh) |
KR (1) | KR20220146547A (zh) |
CN (1) | CN115151249A (zh) |
AU (1) | AU2021225815A1 (zh) |
BR (1) | BR112022016081A2 (zh) |
CA (1) | CA3171359A1 (zh) |
IL (1) | IL295557A (zh) |
MX (1) | MX2022010053A (zh) |
WO (1) | WO2021173550A1 (zh) |
ZA (1) | ZA202209181B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101969979A (zh) * | 2008-03-11 | 2011-02-09 | 昆西生物科学有限公司 | 含有脱辅基水母蛋白的组合物及其使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL137813C (zh) | 1963-05-06 | 1900-01-01 | ||
DE2001017C3 (de) | 1970-01-10 | 1978-05-18 | Hoechst Ag, 6000 Frankfurt | 3,4-Dihydro-1,23-oxathiazin-4on-2,2-dioxide, ihre Herstellung und Verwendung |
PT1890546T (pt) | 2005-05-30 | 2019-01-23 | Antony Benny | Método para melhorar a biodisponibilidade da curcumina |
-
2021
- 2021-02-23 BR BR112022016081A patent/BR112022016081A2/pt unknown
- 2021-02-23 JP JP2022550725A patent/JP2023515129A/ja active Pending
- 2021-02-23 IL IL295557A patent/IL295557A/en unknown
- 2021-02-23 CN CN202180016394.8A patent/CN115151249A/zh active Pending
- 2021-02-23 CA CA3171359A patent/CA3171359A1/en active Pending
- 2021-02-23 EP EP21712359.5A patent/EP4110312A1/en active Pending
- 2021-02-23 WO PCT/US2021/019231 patent/WO2021173550A1/en unknown
- 2021-02-23 MX MX2022010053A patent/MX2022010053A/es unknown
- 2021-02-23 US US17/801,619 patent/US20230078821A1/en active Pending
- 2021-02-23 KR KR1020227032992A patent/KR20220146547A/ko unknown
- 2021-02-23 AU AU2021225815A patent/AU2021225815A1/en active Pending
-
2022
- 2022-08-16 ZA ZA2022/09181A patent/ZA202209181B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101969979A (zh) * | 2008-03-11 | 2011-02-09 | 昆西生物科学有限公司 | 含有脱辅基水母蛋白的组合物及其使用方法 |
Non-Patent Citations (1)
Title |
---|
HABIBOLLAH ESMAILY 等: "An Investigation of the Effects of Curcumin on Anxiety and Depression in Obese Individuals: A Randomized Controlled Trial", 《CHIN J INTEGR MED》, vol. 21, no. 5, 31 May 2015 (2015-05-31), pages 332 - 338, XP035497173, DOI: 10.1007/s11655-015-2160-z * |
Also Published As
Publication number | Publication date |
---|---|
WO2021173550A1 (en) | 2021-09-02 |
JP2023515129A (ja) | 2023-04-12 |
BR112022016081A2 (pt) | 2022-10-04 |
CA3171359A1 (en) | 2021-09-02 |
KR20220146547A (ko) | 2022-11-01 |
US20230078821A1 (en) | 2023-03-16 |
IL295557A (en) | 2022-10-01 |
MX2022010053A (es) | 2022-11-07 |
AU2021225815A1 (en) | 2022-09-08 |
EP4110312A1 (en) | 2023-01-04 |
ZA202209181B (en) | 2024-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101172923B1 (ko) | 신경보호성 건강 보조식품 | |
US20100112099A1 (en) | Phytochemical compositions and methods for activating amp-kinase | |
US20100215782A1 (en) | Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis | |
KR101341648B1 (ko) | 검정콩으로부터 추출한 안토시아닌을 포함하는 정계정맥류 또는 남성 불임의 예방 및 치료용 조성물 | |
JP5508294B2 (ja) | アポイクオリン含有組成物及びその使用方法 | |
JP2024045186A (ja) | アポエクオリンおよびビタミンd含有組成物およびそれらの使用方法 | |
US20230078821A1 (en) | Apoaequorin and Curcumin Containing Compositions and Methods | |
KR101838379B1 (ko) | 자바강황 추출물 또는 잔소리졸을 유효성분으로 함유하는 타액 분비 증강용, 또는 구강건조증 예방, 개선 또는 치료용 조성물 | |
KR102439576B1 (ko) | 뇌기능 개선용 영양전달체 조성물 | |
CN114126594B (zh) | 用于抑制TNF-α或IL-6产生的组合物 | |
JP2022536223A (ja) | ニーム抽出物並びにウロリチンa及びbの相乗作用組み合わせの抗糖尿病活性 | |
US10772866B2 (en) | Pharmaceutical composition for preventing and treating central nervous system diseases containing fluoxetine and vitamin C as active ingredients | |
ES2899548B2 (es) | Kukoamina a para la prevencion y tratamiento de la infeccion viral, preferiblemente por coronavirus | |
CA3192050A1 (en) | Effervescent formulation containing apoaequorin | |
ES2899697B2 (es) | Zeaxantina para la prevencion y tratamiento de la infeccion viral, preferiblemente por coronavirus | |
KR101309137B1 (ko) | C3g 또는 이를 함유하는 오디 추출물을 포함하는 당뇨병성 발기부전의 예방 또는 치료용 조성물 | |
WO2019168149A1 (ja) | 認知機能を改善するペプチド | |
KR0133255B1 (ko) | 액체 발효를 이용한 버섯으로부터의 기능성 건강 식품 및 그의 제조방법 | |
KR101404148B1 (ko) | C3g 또는 이를 함유하는 오디 추출물을 포함하는 당뇨병성 방광병증의 예방 또는 치료용 조성물 | |
BR112019005669B1 (pt) | Composição para tratamento de um sintoma ou transtorno associado a pelo menos um desequilíbrio de cálcio e deficiência de vitamina d, e uso de apoaequorina e vitamina d |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40078493 Country of ref document: HK |